Pfizer to merge unit with Mylan, sending Mylan shares soaring
Under new CEO Albert Bourla, Pfizer has been beefing up its cancer treatment pipeline, buying cancer drugmaker Array Biopharma in June
29 July 2019 - 16:13
Bengaluru — Pfizer will separate its off-patent drugs business and merge it with Mylan, the two companies confirmed on Monday, bringing blockbuster treatments Viagra, EpiPen and Lipitor under one umbrella.
The new company, to be based in the US and incorporated in Delaware, will be helmed by Pfizer's unit president, Michael Goettler, who will become the CEO...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.